沙眼衣原体与淋病奈瑟菌即时检测:文献综述
该综述系统检索5个电子数据库2009年1月至2024年1月的文献,从3743项研究中纳入64项,评估FDA批准的沙眼衣原体和淋病奈瑟菌分子即时检测及近即时检测的性能与实施考虑。截至2025年有4款FDA批准产品,其中3款获CLIA豁免适用于患者就诊时使用;证据提示此类检测在急性诊疗机构中对有症状患者最有益,可减少失访和 empiric 抗生素使用,但仍面临标本类型扩展、周转时间和成本等挑战。
要点
- 截至2025年有4款FDA批准的沙眼衣原体/淋病奈瑟菌即时或近即时检测,其中3款获CLIA豁免。
- 即时检测在急性诊疗机构中对有症状患者最有益,可减少失访和 empiric 抗生素使用。
- 挑战包括需扩展至生殖器外标本、改善周转时间和降低成本。
核心结论
- 部分沙眼衣原体和淋病奈瑟菌即时检测已获监管批准,但在标本类型扩展、周转时间和成本方面仍存挑战,需优化其在急性诊疗机构中的应用。
研究设计与样本
- 系统文献综述,检索5个电子数据库2009年1月至2024年1月的文献,从3743项研究中纳入64项,以叙述形式描述结果。
主要发现
- 截至2025年有4款FDA批准的沙眼衣原体和淋病奈瑟菌即时检测/近即时检测,其中3款获CLIA豁免并适合患者就诊时使用。
- 证据提示即时检测在急性诊疗机构中对有症状患者最有益,可防止失访并减少 empiric 抗生素治疗需求。
关键数值与推荐
- 截至2025年FDA批准的沙眼衣原体和淋病奈瑟菌即时检测/近即时检测共4款,其中3款获CLIA豁免。
临床怎么用
- 在急性诊疗机构中对有症状患者使用CLIA豁免的即时检测,可减少失访和 empiric 抗生素使用。
局限性
- 需扩展标本类型批准至生殖器外标本,需进一步改善周转时间并降低成本以促进采用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Point-of-care tests (POCTs) for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae offer the potential for rapid diagnosis and treatment, improving patient outcomes and reducing disease transmission. We sought to compile evidence on the accuracy and clinical utility of molecular-based POCTs and near-POCTs for the detection of C. trachomatis and N. gonorrhoeae. METHODS: We performed a systematic literature search of 5 electronic databases from January 2009 to January 2024 to understand the performance characteristics and implementation considerations associated with Food and Drug Administration-cleared POCTs and near-POCTs. Results were described in a narrative format. RESULTS: From 3743 identified studies, 64 met our inclusion criteria. As of 2025, there are 4 Food and Drug Administration-cleared POCTs/near-POCTs for detecting C. trachomatis and N. gonorrhoeae, 3 of which are waived by the Clinical Laboratory Improvement Amendments and suitable for use during a patient visit. Evidence suggests that POCTs are most beneficial in symptomatic patients within acute care settings, where they can prevent loss to follow-up and reduce the need for empiric antibiotic treatment. CONCLUSIONS: While some POCTs for C. trachomatis and N. gonorrhoeae have achieved regulatory clearance, challenges remain, including the need to expand specimen type clearance to include extragenital specimens, to further improve turnaround times, and to decrease cost for adoption. There is need to optimize the use of POCTs in acute care settings to manage sexually transmitted infections.
引用
- Manabe YC, Smith AC, Trow S, et al. Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature. Clin Infect Dis. 2026. PMID: 41733546. doi:10.1093/cid/ciaf699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。